AU2012322445B2 - Canine/feline CD20 binding epitope and compositions for binding thereto - Google Patents

Canine/feline CD20 binding epitope and compositions for binding thereto Download PDF

Info

Publication number
AU2012322445B2
AU2012322445B2 AU2012322445A AU2012322445A AU2012322445B2 AU 2012322445 B2 AU2012322445 B2 AU 2012322445B2 AU 2012322445 A AU2012322445 A AU 2012322445A AU 2012322445 A AU2012322445 A AU 2012322445A AU 2012322445 B2 AU2012322445 B2 AU 2012322445B2
Authority
AU
Australia
Prior art keywords
amino acid
seq
acid sequence
antibody
canine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012322445A
Other languages
English (en)
Other versions
AU2012322445A1 (en
Inventor
David Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexvet Australia Pty Ltd
Original Assignee
Nexvet Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexvet Australia Pty Ltd filed Critical Nexvet Australia Pty Ltd
Publication of AU2012322445A1 publication Critical patent/AU2012322445A1/en
Assigned to NEXVET AUSTRALIA PTY LTD reassignment NEXVET AUSTRALIA PTY LTD Request for Assignment Assignors: NVIP PTY LTD
Application granted granted Critical
Publication of AU2012322445B2 publication Critical patent/AU2012322445B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
AU2012322445A 2011-10-13 2012-10-12 Canine/feline CD20 binding epitope and compositions for binding thereto Ceased AU2012322445B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546865P 2011-10-13 2011-10-13
US61/546,865 2011-10-13
PCT/GB2012/052532 WO2013054127A1 (en) 2011-10-13 2012-10-12 Canine/feline cd20 binding epitope and compositions for binding thereto

Publications (2)

Publication Number Publication Date
AU2012322445A1 AU2012322445A1 (en) 2014-04-24
AU2012322445B2 true AU2012322445B2 (en) 2016-12-15

Family

ID=47023030

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012322445A Ceased AU2012322445B2 (en) 2011-10-13 2012-10-12 Canine/feline CD20 binding epitope and compositions for binding thereto

Country Status (7)

Country Link
US (1) US20140294819A1 (enExample)
EP (1) EP2766391A1 (enExample)
JP (1) JP2015501146A (enExample)
AU (1) AU2012322445B2 (enExample)
CA (1) CA2851758A1 (enExample)
HK (1) HK1201281A1 (enExample)
WO (1) WO2013054127A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113173993B (zh) 2013-12-20 2024-03-08 英特维特国际股份有限公司 拮抗性抗犬pd-1抗体
WO2017142800A1 (en) 2016-02-18 2017-08-24 Eli Lilly And Company Chimeric canine anti-cd20 antibody
WO2019164821A1 (en) * 2018-02-20 2019-08-29 Memorial Sloan Kettering Cancer Center Anti-cd20 antibody and uses thereof
EP3999539A1 (en) * 2019-07-15 2022-05-25 Intervet International B.V. Caninized antibodies to human and canine ctla-4
EP4021499A4 (en) * 2019-08-29 2024-08-07 Elanco US Inc. ANTI-IL31 ANTIBODIES FOR VETERINARY USE
JP2021059499A (ja) 2019-10-03 2021-04-15 日本全薬工業株式会社 イヌｃｄ２０に対するモノクローナル抗体又は抗体フラグメント
BR112023026592A2 (pt) * 2021-06-17 2024-03-05 Petmedix Ltd Anticorpos cd20 anti-canino

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US20050271662A1 (en) * 2004-05-28 2005-12-08 Idexx Laboratories, Inc. Canine CD20 compositions
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
US20110091483A1 (en) * 2004-05-28 2011-04-21 Idexx Laboratories, Inc. Canine Anti-CD20 Antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4263951B2 (ja) * 2003-06-20 2009-05-13 財団法人日本生物科学研究所 イヌ化抗体の作成方法および使用
TWI432453B (zh) * 2008-01-11 2014-04-01 Astellas Pharma Inc 改良型人化抗人α９整連蛋白抗體

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
US20050271662A1 (en) * 2004-05-28 2005-12-08 Idexx Laboratories, Inc. Canine CD20 compositions
US20110091483A1 (en) * 2004-05-28 2011-04-21 Idexx Laboratories, Inc. Canine Anti-CD20 Antibodies
WO2010027488A2 (en) * 2008-09-04 2010-03-11 Vet Therapeutics, Inc. Monoclonal antibodies
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEIDERFELLNER G. J., et al, "Unique molecular recognition of CD20 by the type II CD20 antibody GA101", European Journal of Cancer, 2010, vol 8, pages 75-76, abstract 232 *
TEELING J. L., et al, "The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20", The Journal of Immunology, 2006, vol 177, pages 362-371 *

Also Published As

Publication number Publication date
AU2012322445A1 (en) 2014-04-24
WO2013054127A1 (en) 2013-04-18
JP2015501146A (ja) 2015-01-15
HK1201281A1 (en) 2015-08-28
EP2766391A1 (en) 2014-08-20
US20140294819A1 (en) 2014-10-02
NZ623644A (en) 2015-03-27
CA2851758A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
US12084499B2 (en) SIRP-α binding proteins and methods of use thereof
CN111051347B (zh) Tigit抗体、其抗原结合片段及医药用途
CN106029695B (zh) 拮抗性抗犬pd-1抗体
EP3424953B1 (en) Therapeutic antibodies
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
AU2012322445B2 (en) Canine/feline CD20 binding epitope and compositions for binding thereto
CN111699196A (zh) 针对lilrb2的抗体
US20230120270A1 (en) New polypeptide complex
CN110392694A (zh) 针对pd-1的抗体及其用途
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
CN112513088B (zh) 抗ox40抗体、其抗原结合片段及其医药用途
EP3851456A1 (en) Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
US20200102387A1 (en) SIRP-Alpha BINDING PROTEINS AND METHODS OF USE THEREOF
CN117616049A (zh) Fap/cd40结合分子及其医药用途
CN111183153A (zh) Cd3/cd33双特异性结合分子
EP3647323A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN114174337A (zh) 针对犬ctla-4的犬源化抗体
US20250270346A1 (en) Efficacious anti-cd26 antibody biomarker
NZ623644B2 (en) Canine/feline cd20 binding epitope and compositions for binding thereto
RU2800779C2 (ru) Биспецифичные антигенсвязывающие молекулы и способы их применения
HK40038468A (en) Antibodies to lilrb2
HK40045553A (en) Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NEXVET AUSTRALIA PTY LTD

Free format text: FORMER APPLICANT(S): NVIP PTY LTD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired